中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD

文献类型：期刊论文

作者He, Yong6,7; Chen, Yingfen6,7; Qian, Shengying6,7; van der Merwe, Schalk4,5; Dhar, Debanjan2,3; Brenner, David A.2,3; Tacke, Frank1
刊名CELLULAR & MOLECULAR IMMUNOLOGY
出版日期2025-06-10
页码19
关键词MASLD MASH inflammation pathogenesis.
ISSN号1672-7681
DOI10.1038/s41423-025-01307-5
英文摘要Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is the most prevalent chronic liver disease worldwide, with an estimated global prevalence of approximately 30%; however, effective pharmacotherapies are still limited due to its complex pathogenesis and etiology. Therefore, a more thorough understanding of disease pathogenesis is urgently needed. An increasing number of studies suggest that MASLD and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are driven by chronic overnutrition, multiple genetic susceptibility factors, and pathogenic consequences, including hepatocyte damage and liver inflammation. Hepatic inflammation is the key event fueling the conversion from simple steatosis to steatohepatitis and fibrosis. Current therapies for MASH, including the recently approved thyroid hormone receptor-beta agonist resmetirom or the available incretin mimetics, mainly target metabolic injury to the liver but not inflammation directly. In this review, we provide an in-depth discussion of current data related to the immunological mechanisms of MASLD and summarize the effects of current and experimental therapies on immunoregulation in MASLD.
WOS关键词HEPATIC STELLATE CELLS ; FATTY LIVER-DISEASE ; METABOLIC DYSFUNCTION ; T-CELLS ; KUPFFER CELLS ; NONALCOHOLIC STEATOHEPATITIS ; INSULIN-RESISTANCE ; RECEPTOR AGONISTS ; CONTROLLED-TRIAL ; CUTTING EDGE
资助项目National Science and Technology Innovation 2030 Major Program[2024ZD0530604] ; National Key Research and Development Program of China[2023YFA1800804] ; National Natural Science Foundation of China, China[82270601] ; German Research Foundation[403224013] ; U.S. National Institutes of Health[R01DK137061] ; U.S. National Institutes of Health[R01DK133930]
WOS研究方向Immunology
语种英语
WOS记录号WOS:001505261200001
出版者CHIN SOCIETY IMMUNOLOGY
源URL[http://119.78.100.183/handle/2S10ELR8/318297]  
专题新药研究国家重点实验室
通讯作者He, Yong; Tacke, Frank
作者单位1.Charite Univ Med Berlin, Dept Hepatol & Gastroenterol, Campus Virchow Klinikum & Campus Charite Mitte, Berlin, Germany
2.Sanford Burnham Prebys Med Discovery Inst, Ctr Metab & Liver Dis, Canc Genome & Epigenet Program, La Jolla, CA USA
3.Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA USA
4.UZ Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
5.Katholieke Univ Leuven, CHROMETA Dept, Lab Hepatol, Leuven, Belgium
6.Univ Chinese Acad Sci, Beijing, Peoples R China
7.Chinese Acad Sci, Shanghai Inst Mat Med SIMM, State Key Lab Drug Res, Shanghai, Peoples R China
推荐引用方式
GB/T 7714		 He, Yong,Chen, Yingfen,Qian, Shengying,et al. Immunopathogenic mechanisms and immunoregulatory therapies in MASLD[J]. CELLULAR & MOLECULAR IMMUNOLOGY,2025:19.
APA He, Yong.,Chen, Yingfen.,Qian, Shengying.,van der Merwe, Schalk.,Dhar, Debanjan.,...&Tacke, Frank.(2025).Immunopathogenic mechanisms and immunoregulatory therapies in MASLD.CELLULAR & MOLECULAR IMMUNOLOGY,19.
MLA He, Yong,et al."Immunopathogenic mechanisms and immunoregulatory therapies in MASLD".CELLULAR & MOLECULAR IMMUNOLOGY (2025):19.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。